Health Capital Helsinki
  • Home
  • Why Helsinki Metropolitan
  • About
  • News
  • Events
  • Opportunities
  • Careers
  • Contact
  • Search
  • Menu Menu
Keksi Agency / City of Helsinki
Sep 10, 2021

Role reversal: Big Pharma to pitch to startups in new event

Amgen, Pfizer and Takeda hold court in the first-ever Nordic Big Pharma Reverse Pitching Event. Hosted virtually on 15 September, 2021, the event comes free of charge for the participants.

The Reverse Pitching Event is sponsored by Amgen, Pfizer and Takeda and organized by Health Capital Helsinki in collaboration with HealthTech Nordic and Health Founders from Estonia.

In the event, there will be an exclusive opportunity for startups, scaleups, researchers and pharma industry to get introduced and initiate collaboration, explains Director Juha Paakkola from Health Capital Helsinki.

– Startups don’t always understand how Big Pharma works, but there is tremendous potential inherent in collaboration, once the two sides get acquainted. This is an effective meeting platform for Big Pharma and startups to explore synergies in depth, Paakkola says.

The event kicks off with 10-minute reverse pitches by the sponsoring pharma companies: in the pitches, they present their offering and special innovation needs. After the presentations, there’s time for Q&A and panel discussion before pre-booked one-on-one meetings with the pharma companies.

Register for the event

Developing Health & Wellbeing is a mutual target

Niilo Färkkilä, Country Director, Finland and Baltics, at Amgen says that building versatile networks is essential for all Big Pharma companies today.

– We want to strengthen our collaboration base with startups. The Finnish Health & Wellbeing startups possess a vast range of ideas and expertise that hold also export potential, Färkkilä says.

Hannes Toivanen, Strategic Partnerships Lead at Takeda, comments that developing the Finnish Health & Wellbeing ecosystem is a common target for companies both big and small.

Startups don’t always understand how Big Pharma works, but there is tremendous potential inherent in collaboration, once the two sides get acquainted.

– We are looking for startups to innovate with us, with a special focus on Nordic Deep Tech companies. In the event, we want to talk about our current needs and the value of partnership as we perceive it, says Toivanen.

Deb Mangone, Country Director at Pfizer, says that she’s excited about meeting innovative growth companies in a setting that differs from the norm.

– We want to talk with the startups to find out just how we can support them. Elevating the level of industry innovation in Finland is a big priority for us, Mangone says.

Keksi Agency / City of Helsinki

“Health tech in Finland and in the Nordics is now entering a super exciting phase – and we feel that our event supports this evolution perfectly.”

Healthcare breakthroughs are achieved in collaboration

Amgen, Pfizer and Takeda are participating in the event, since they believe that promoting the cause of the industry takes precedence over the business interests of a single company. Färkkilä, Toivanen and Mangone all agree that here is a great chance to do something that can give the entire sector a boost.

– Healthcare as a whole is our common challenge: what can we do together in order to secure the next wave of responsible innovation, Niilo Färkkilä says, adding that Health & Wellbeing is definitely a growth sector for the future.

Lowering the threshold between Big Pharma companies and startups is key:

– Big Pharma can appear a bit faceless, so we’re hoping this event will help us to interact and engage more effortlessly with startups, says Hannes Toivanen.

Deb Mangone agrees that startups may find it difficult to relate to Big Pharma – especially if the startup’s innovation is not quite “fully baked” yet.

– Sometimes the industry connection is less obvious, but we want to become that important stakeholder and thought partner for startups that can help them go forward. Transformative breakthroughs are mostly achieved as collaborations, she points out.

In early September, already 200 people from 120 startups have registered for the event. Juha Paakkola says that the opportunity to gain insight into the mindset of not one, but three Big Pharma players, is clearly an attractive one from the perspective of the startups.

– Health tech in Finland and in the Nordics is now entering a super exciting phase – and we feel that our event supports this evolution perfectly, Paakkola says, adding that Health Capital Helsinki, as the organizer, wants to host Nordic Big Pharma Reverse Pitching Event every year from now on.

For additional information, please contact:

Juha Paakkola

Juha Paakkola

Director, Health Capital Helsinki
juha.paakkolahealthcapitalhelsinki.fiHealth Capital Helsinki
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn

News

Health Capital Helsinki

Three friends looking at sea in Tervasaari Island in HelsinkiHelsinki Partners / Aleksi Poutanen

Helsinki partners with the new Radical Health Festival Helsinki 2023

Jan 25, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2023/01/Friends_on_the_shore_AleksiPoutanen.jpg 1654 2480 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-01-25 11:09:352023-01-30 11:26:25Helsinki partners with the new Radical Health Festival Helsinki 2023
Slush 2022Slush

SCellex – Winner of the Y Science Health Pitching Competition at Slush 2022

Jan 18, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2023/01/Slush_2-2022_Janne_Nuolioja.jpg 1333 2000 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-01-18 14:16:162023-01-18 14:39:19SCellex – Winner of the Y Science Health Pitching Competition at Slush 2022
Wintery landscape from Kalasatama, HelsinkiJanne Hirvonen / Helsinki Partners

Finnish cardiovascular device company HVR Cardio secures EUR10M financing

Jan 12, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2023/01/220105_Talvinen_merimaisema_vastavaloon_©Janne_Hirvonen.jpg 1653 2480 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-01-12 11:18:572023-01-30 14:06:23Finnish cardiovascular device company HVR Cardio secures EUR10M financing
All news

Health Capital Helsinki

Helsinki Partners
Kasarmikatu 36
00130 HELSINKI
FINLAND

Privacy notice

Sign up to our newsletter

Subscribe

Follow us

  • twitter
  • linkedin
Health Capital Helsinki
Scroll to top

We use cookies to give you the best experience on our website.

Find out more and set your preferences settings.

Powered by  GDPR Cookie Compliance
How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential website cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are necessary to deliver the website as intended, refusing them will have impact how our site functions. You can always block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will prompt you to accept or refuse cookies every time you revisit our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Third party cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.

We also use Twitter's and LinkedIn's cookies to help us improve our content and reach.

Please enable essential website cookies first so that we can save your preferences!

Privacy notice

You can read about how we use your data on our Privacy notice page.

Privacy notice